Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,571.78 55.51 0.38%
TOPIX 1,175.44 2.07 0.18%
HANG SENG 22,760.24 64.23 0.28%

Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013



Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On
                            Monday, March 18, 2013

PR Newswire

LAWRENCEVILLE, N.J., March 12, 2013

LAWRENCEVILLE, N.J., March 12, 2013 /PRNewswire/ -- Celsion Corporation
(NASDAQ: CLSN), a leading oncology drug development company, today announced
that it will hold a conference call to discuss year-end 2012 results at 11:00
a.m. ET on Monday, March 18, 2013. To participate in the call, interested
parties may dial 1-888-312-3048 (Toll-Free/North America) or 1-719-457-1512
(International/Toll) and ask for The Celsion Corporation Year-End 2012
Financial Results Conference Call to register ten minutes before the call is
scheduled to begin. The call will also be broadcast live on the internet at
http://www.celsion.com.

The call will be archived for replay on Monday, March 18, 2013 at 2:00 p.m. ET
and will remain available until Monday, April 1, 2013. The replay can be
accessed at 1-877-870-5176 (Toll-Free/North America) or 1-858-384-5517
(International/Toll) using Conference ID: 4075429. An audio replay of the call
will also be available on the Company's website, http://www.celsion.com, for
30 days after 2:00 p.m. ET on Monday, March 18, 2013.

About Celsion Corporation

Celsion is a leading oncology company dedicated to the development and
commercialization of innovative cancer drugs including tumor-targeting
treatments using focused heat energy in combination with heat-activated
liposomal drug technology. Celsion has research, license, or commercialization
agreements with leading institutions such as the National Institutes of
Health, Duke University Medical Center, University of Hong Kong, the
University of Pisa, the UCLA Department of Medicine, the Kyungpook National
University Hospital, the Beijing Cancer Hospital and the University of Oxford.

For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this
release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials by others; possible acquisitions of other
technologies, assets or businesses; possible actions by customers, suppliers,
competitors, regulatory authorities; and other risks detailed from time to
time in the Company's periodic reports filed with the Securities and Exchange
Commission.

Investor Contact

Jeffrey W. Church
Sr. Vice President – Corporate Strategy &
Investor Relations
609-482-2455
jchurch@celsion.com

SOURCE Celsion Corporation

Website: http://www.celsion.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement